Symbiotec Pharmalab IPO Description – Symbiotec Pharmalab operates as a vertically integrated pharmaceutical and biotechnology player with capabilities spanning APIs, CDMO services, and complex injectables. Its business model is built on a “microbe-to-pharmacy” and “farm-to-pharmacy” approach, enabling control over the entire value chain—from raw material sourcing and fermentation to finished dosage forms. It has a strong global footprint, supplying products to over 200 customers across 40+ countries, including regulated markets such as the US and Europe.
The company holds leadership positions in key corticosteroid and steroidal hormone APIs, with market shares exceeding 50% in molecules like Hydrocortisone (78.9%), Testosterone (70.4%), and Methylprednisolone (50.6%). Manufacturing capabilities include chemical synthesis capacity of ~585 MT, fermentation capacity of 700 KL, and injectables capacity of 20 million vials annually. Backward integration allows in-house production of key starting materials for over 80% of its portfolio, ensuring cost efficiency and supply chain reliability. As of 30 June 2025, the company has 1,752 full-time employees.
Promoters of Symbiotec Pharmalab – Anil Satwani, Kashish Satwani, Sushil Satwani and Satwani Holdings LLP
Symbiotec Pharmalab IPO Details
| Symbiotec Pharmalab IPO Dates | Coming soon |
| Symbiotec Pharmalab Issue Price | Coming soon |
| Fresh Issue | INR 150 crore |
| Offer For Sale | INR 2,030 crore |
| Total IPO Size | INR 2,180 crore |
| Minimum Bid (Lot Size) | Coming soon |
| Pre-issue Shares | 6,16,81,496 shares |
| Face Value | INR 2 per share |
| Listing On | NSE, BSE |
Symbiotec Pharmalab IPO Allocation in Different Categories
Symbiotec Pharmalab Financial Performance
| FY 2023 | FY 2024 | FY 2025 | Q1 FY 2025 | |
| Revenue | 566.51 | 716.25 | 751.55 | 203.17 |
| Expenses | 533.63 | 590.99 | 608.85 | 160.99 |
| Net Income | 23.49 | 100.06 | 96.79 | 29.92 |
| Margin (%) | 4.15 | 13.97 | 12.88 | 14.73 |
Symbiotec Pharmalab Offer News
Symbiotec Pharmalab Valuations & Margins
| FY 2023 | FY 2024 | FY 2025 (Pre-Issue) | FY 2026* (Post-Issue) | |
| EPS | 4.29 | 18.32 | 17.67 | – |
| PE Ratio | – | – | – | – |
| Price/Sales Ratio | – | – | – | – |
| Price/Book Ratio | – | – | – | – |
| Current Ratio | – | – | – | – |
| FY 2023 | FY 2024 | FY 2025 | |
| RONW (%) | 3.78 | 13.90 | 11.79 |
| NAV | 113.60 | 131.79 | 150.17 |
| ROCE (%) | 5.31 | 14.03 | 11.80 |
| EBITDA (%) | 12.96 | 24.48 | 27.26 |
| Debt/Equity | 0.35 | 0.34 | 0.64 |
Evaluate the quality of an IPO using these essential investing ratios to make an informed decision.
Symbiotec Pharmalab IPO Anchor Investors
Symbiotec Pharmalab raises () from anchor investors. Symbiotec Pharmalab Anchor bid date is ().
| Bid Date | Coming soon |
| Shares Offered | Coming soon |
| Anchor Portion (INR Cr.) | Coming soon |
| Anchor lock-in period end date for 50% shares (30 Days) | Coming soon |
| Anchor lock-in period end date for remaining shares (90 Days) | Coming soon |
Symbiotec Pharmalab IPO GMP Today (Daily Trend)
Symbiotec Pharmalab Offer Objectives
The company proposes to utilize net proceeds from the issue towards the following objects:
- Prepayment/repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the company – INR 112.5 crore
- General Corporate Purposes
Symbiotec Pharmalab IPO Subscription – Live Updates
Coming soon
() shares allotted to anchor investors are not included in these calculations.
Symbiotec Pharmalab – Comparison With Listed Peers
| Company | PE ratio | EPS | RONW (%) | NAV | Revenue (Cr.) |
| Symbiotec Pharmalab | – | 17.67 | 11.79 | 150.17 | 821 |
| Concord Biotech | 38.59 | 35.52 | 22.00 | NA | 59,358 |
| Divi’s Laboratories | 77.87 | 82.53 | 14.83 | 562 | 1,427 |
| Cohance Lifesciences | 42.31 | 12.68 | 19.10 | NA | 106 |
| Laurus Labs | 152.85 | 6.64 | 8.00 | 82.95 | 1,725 |
Symbiotec Pharmalab IPO Allotment Status
You can check Symbiotec Pharmalab IPO allotment status on MUFG Intime’s website. Click on this link to get the allotment status. Often not getting IPO allotment? Learn how to improve your IPO allotment chances.
Symbiotec Pharmalab IPO Dates & Listing Performance
| IPO Opening Date | Coming soon |
| IPO Closing Date | Coming soon |
| Finalization of Basis of Allotment | Coming soon |
| Initiation of refunds | Coming soon |
| Transfer of shares to demat accounts | Coming soon |
| Symbiotec Pharmalab IPO Listing Date | Coming soon |
| Opening Price on NSE | Coming soon |
| Closing Price on NSE | Coming soon |
Symbiotec Pharmalab IPO Reviews – Subscribe or Avoid?
Angel One –
Anand Rathi –
Axis Capital –
Antique Stock Broking –
Arihant Capital –
Ashika Research –
Asit C Mehta –
BP Wealth –
Capital Market –
Canara Bank Securities –
Choice Broking –
Dalal & Broacha –
Elite Wealth –
GCL Broking –
Geojit –
GEPL Capital –
Hem Securities –
ICICIdirect –
Investmentz –
Jainam Broking –
DR Choksey –
LKP Research –
Marwadi Financial –
Motilal Oswal –
Nirmal Bang –
Reliance Securities –
SBI Securities –
Samco Securities –
SMC Global –
Swastika Investmart –
Ventura Securities –
Symbiotec Pharmalab IPO Lead Manager
JM FINANCIAL LIMITED
7TH Floor, Cnergy Appasaheb Marathe Marg
Prabhadevi, Mumbai 400 025, Maharashtra, India
Tel: +91 22 6630 3030
E-mail: [email protected]
Website: www.jmfl.com
Symbiotec Pharmalab Offer Registrar
MUFG INTIME (LINK INTIME) INDIA PRIVATE LIMITED
C-101, 1st Floor, 247 Park L.B.S. Marg,
Vikhroli West, Mumbai – 400 083, Maharashtra
Telephone: +91 810 811 4949
Email: [email protected]
Website: www.in.mpms.mufg.com
SYMBIOTEC PHARMALAB LIMITED
385/2, Pigdamber, Rau, Mhow,
Indore – 453 331, Madhya Pradesh, India
Phone: +91 731 667 6405
Email: [email protected]
Website: www.symbiotec.com
IPO Resources
How many shares in Symbiotec Pharmalab IPO are reserved for HNIs and retail investors?
The investors’ portion for QIB – 50%, NII – 15%, and Retail – 35%.
How to apply in Symbiotec Pharmalab Public Offer?
What is Symbiotec Pharmalab IPO GMP today?
Symbiotec Pharmalab IPO GMP today is INR NA per share.
What is Symbiotec Pharmalab Subject to Sauda rate today?
Symbiotec Pharmalab Subject to Sauda rate today is INR NA per application.
Krishna comes from a family of investors and financial analysts, She learnt wading through regulatory filings pretty early in her career. She has several years of experience in financial and industry analysis under her belt. At IPO Central, Krishna plays twin roles of Contributor and Head of research desk.
